Large Animal Models for Vaccine Development and Testing

• Published in: ILAR journal Vol. 56; no. 1; pp. 53 - 62
• Main Authors: Gerdts, Volker, Wilson, Heather L., Meurens, Francois, van Drunen Littel - van den Hurk, Sylvia, Wilson, Don, Walker, Stewart, Wheler, Colette, Townsend, Hugh, Potter, Andrew A.
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.01.2015; Oxford University Press (OUP): Policy E - Oxford Open Option E
• Subjects: Animals; Disease Models, Animal; Life Sciences; Vaccines; animal models; vaccine; vaccine efficacy; large animals; Large animals; Animal models; Vaccine; Vaccine efficacy
• ISSN: 1084-2020; 1930-6180; 1930-6180
• DOI: 10.1093/ilar/ilv009

The development of human vaccines continues to rely on the use of animals for research. Regulatory authorities require novel vaccine candidates to undergo preclinical assessment in animal models before being permitted to enter the clinical phase in human subjects. Substantial progress has been made in recent years in reducing and replacing the number of animals used for preclinical vaccine research through the use of bioinformatics and computational biology to design new vaccine candidates. However, the ultimate goal of a new vaccine is to instruct the immune system to elicit an effective immune response against the pathogen of interest, and no alternatives to live animal use currently exist for evaluation of this response. Studies identifying the mechanisms of immune protection; determining the optimal route and formulation of vaccines; establishing the duration and onset of immunity, as well as the safety and efficacy of new vaccines, must be performed in a living system. Importantly, no single animal model provides all the information required for advancing a new vaccine through the preclinical stage, and research over the last two decades has highlighted that large animals more accurately predict vaccine outcome in humans than do other models. Here we review the advantages and disadvantages of large animal models for human vaccine development and demonstrate that much of the success in bringing a new vaccine to market depends on choosing the most appropriate animal model for preclinical testing.